NECFA
TLIS

New England Capital Financial Advisors’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

New England Capital Financial Advisors’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1
Closed -$6 – 414
2023
Q3 		$6 Hold
1
– – ﹤0.01% 395
2023
Q2 		$5 Hold
1
– – ﹤0.01% 391
2023
Q1 		$5 Hold
1
– – ﹤0.01% 436
2022
Q4 		$6 Buy
+1
New +$9 ﹤0.01% 441

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

New England Capital Financial Advisors's TLIS Position: Q4 2023 in Review

New England Capital Financial Advisors sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q4 2023, closing a stake of 1 share — an estimated $6 sold.

New England Capital Financial Advisors first reported a position in TLIS in Q4 2022 and held it in 4 quarters. The position peaked at $6 in Q3 2023. 18 funds tracked by Wall St. Rank hold TLIS as of Q4 2023.

  • New England Capital Financial Advisors reported no remaining Talis Biomedical Corporation Common Stock position as of Q4 2023 after selling out during the quarter.
  • New England Capital Financial Advisors sold 1 Talis Biomedical Corporation Common Stock share in Q4 2023, an estimated $6.
  • New England Capital Financial Advisors first reported a position in Talis Biomedical Corporation Common Stock in Q4 2022 and held it in 4 quarters.
  • New England Capital Financial Advisors's Talis Biomedical Corporation Common Stock position peaked at $6 in Q3 2023.
  • 18 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q4 2023.

Based on New England Capital Financial Advisors's 13F filing for Q4 2023, filed 1 Feb 2024.